Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 77c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.77).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Stifel on EyePoint Inc. (EYPT): 'we think these data bode well for LUCIA (expected October) barring another unusual asymmetry'
• NAHB housing market index rises to 35 in August from 34